Table 5.

Summary of dose optimization for DDI under the influence of other factors.

Factors	Genotype	AUC (μmol min/L)	CF	ΔD
Genotype	NM	755.26	0.99	1%
	IM	865.09	0.86	14%※
	PM	1036.57	0.72	28%※
	UM	758.19	0.99	1%
Mild hepatic impairment	NM	842.20	0.89	11%※
Genotype and mild hepatic impairment	NM	842.20	0.89	11%※
	IM	1231.96	0.61	39%※
	PM	1466.17	0.51	49%※
	UM	840.33	0.89	11%※

^※represents requiring a dosage reduction.

AUC, area under the cure; CF, correction factor indicates correction factors describing the effect of liver cirrhosis on hepatic metabolic activity; ΔD, changes of dose; DGI, drug–gene interaction; DDZI, drug–disease interaction; IM, intermediate metabolizer; NM, normal metabolizer; PM, poor metabolizer; UM, ultrarapid metabolizer.